

Sharon Bio - Medicine Limited
 Statement of Standalone Unaudited Financial Results for the half year ended September 30, 2021

(₹. In Lakhs) (except per share data)

| Sr. No. | Particulars | Quarter Ended | | | Six Months Ended | | Year Ended |
|---------|--|-----------------|-----------------|-----------------|------------------|-----------------|------------------|
| | | Sept 30, 2021 | June 30, 2021 | Sept 30, 2020 | Sept 30, 2021 | Sept 30, 2020 | Mar 31, 2021 |
| | | Unaudited | Unaudited | Unaudited | Unaudited | Unaudited | Audited |
| (i) | Gross Revenue from sale of products and services | 4,519.42 | 4,799.95 | 4,189.20 | 9,319.37 | 7,621.56 | 16,487.65 |
| (ii) | Other operating revenue | 18.47 | 88.76 | 136.21 | 107.24 | 284.09 | 798.58 |
| 1 | REVENUE FROM OPERATIONS[(i)+(ii)] | 4,537.89 | 4,888.72 | 4,325.41 | 9,426.61 | 7,905.65 | 17,286.22 |
| 2 | Other Income | 47.08 | 65.67 | 64.10 | 112.76 | 101.60 | 410.52 |
| 3 | TOTAL INCOME (1+2) | 4,584.98 | 4,954.39 | 4,389.51 | 9,539.37 | 8,007.25 | 17,696.74 |
| 4 | EXPENSES | | | | | | |
| a | Cost of materials Consumed | 2,466.83 | 2,297.12 | 2,397.09 | 4,763.94 | 4,256.06 | 9,173.65 |
| b | Changes in inventories | (220.05) | 272.94 | (196.04) | 52.89 | (126.43) | (546.26) |
| c | Employee benefits expense | 731.14 | 785.91 | 800.02 | 1,517.05 | 1,436.75 | 3,052.23 |
| d | Depreciation and amortization expense | 281.53 | 275.63 | 287.87 | 557.16 | 571.27 | 1,151.25 |
| e | Finance costs | 2.90 | 3.19 | 4.38 | 6.09 | 8.75 | 17.49 |
| f | Other expenses | 874.94 | 870.18 | 858.77 | 1,745.12 | 1,473.50 | 3,443.73 |
| | TOTAL EXPENSES | 4,137.28 | 4,504.97 | 4,152.08 | 8,642.26 | 7,619.89 | 16,292.08 |
| 5 | PROFIT BEFORE EXCEPTIONAL ITEMS AND TAX (3-4) | 447.69 | 449.42 | 237.43 | 897.11 | 387.36 | 1,404.66 |
| 6 | EXCEPTIONAL ITEMS | - | - | - | - | - | - |
| 7 | PROFIT BEFORE TAX (5-6) | 447.69 | 449.42 | 237.43 | 897.11 | 387.36 | 1,404.66 |
| 8 | Tax Expenses | - | - | - | - | - | - |
| 9 | PROFIT FOR THE PERIOD (7-8) | 447.69 | 449.42 | 237.43 | 897.11 | 387.36 | 1,404.66 |
| 10 | OTHER COMPREHENSIVE INCOME | | | | | | |
| A(i) | Items that will not be reclassified to profit or loss | - | - | - | - | - | 23.81 |
| A(ii) | Income tax relating to items that will not be reclassified to profit or loss | - | - | - | - | - | - |
| 11 | TOTAL COMPREHENSIVE INCOME (9+10) | 447.69 | 449.42 | 237.43 | 897.11 | 387.36 | 1,428.47 |
| 12 | PAID UP EQUITY SHARE CAPITAL (of Rs.2/- each) | 115.11 | 115.11 | 2,378.71 | 2,378.71 | 2,378.71 | 115.11 |
| 13 | OTHER EQUITY | | | | | | |
| | EARNINGS PER SHARE (of Rs 2/- each) (not annualised) | | | | | | |
| a | Basic (Rs.) | 7.78 | 7.81 | 0.20 | 0.75 | 0.33 | 24.41 |
| b | Diluted (Rs.) | - | - | - | - | - | - |



Sharon Bio - Medicine Limited
Statement of Assets & Liabilities as at Sep 30, 2021 (Standalone)

(₹. In Lakhs)

| Particulars | As at Sep 30, 2021 | As at March 31, 2021 |
|---|--------------------|----------------------|
| | Unaudited | Audited |
| ASSETS | | |
| Non-current assets | | |
| (a) Property, Plant and Equipment | 13,665.94 | 13,989.48 |
| (b) Capital work-in-progress | 31.94 | 0.24 |
| (c) Right to use of Assets | 130.63 | 158.82 |
| (d) Financial Assets | | |
| (i) Investments | 0.13 | 0.13 |
| (ii) Loans & Advances | 89.21 | 62.69 |
| (e) Other Financial Assets | 6.00 | 6.00 |
| (f) Other non-current assets | 859.95 | 857.04 |
| | 14,783.79 | 15,074.40 |
| Current assets | | |
| (a) Inventories | 4,438.37 | 4,931.83 |
| (b) Financial Assets | | |
| (i) Trade receivables | 2,858.32 | 2,927.98 |
| (ii) Cash and cash equivalents | 1,387.59 | 1,276.21 |
| (iii) Bank balances other than (ii) above | 3,812.40 | 1,912.40 |
| (c) Other current assets | 2,639.23 | 2,897.68 |
| | 15,135.91 | 13,946.10 |
| TOTAL ASSETS | 29,919.70 | 29,020.50 |
| EQUITY AND LIABILITIES | | |
| Equity | | |
| (a) Equity Share capital | 115.11 | 115.11 |
| (b) Other equity | (61,764.87) | (62,661.97) |
| | (61,649.76) | (62,546.86) |
| Non-current liabilities | | |
| (a) Financial Liabilities | | |
| (i) Long term borrowings | 55,801.72 | 55,801.72 |
| (ii) Other financial liabilities | 78.17 | 112.57 |
| (b) Long term provisions | 593.07 | 538.26 |
| | 56,472.96 | 56,452.55 |
| Current liabilities | | |
| (a) Financial Liabilities | | |
| (i) Short term borrowings | 26,930.68 | 26,930.68 |
| (ii) Lease Liability -Current | 68.70 | 62.89 |
| (iii) Trade and other payables (MSME) | 168.11 | 195.62 |
| (iv) Trade and other payables | 4,261.94 | 4,119.67 |
| (v) Other financial liabilities | 24.78 | 24.78 |
| (b) Other current liabilities | 3,594.20 | 3,704.16 |
| (c) Short-term provisions | 48.09 | 77.02 |
| | 35,096.50 | 35,114.81 |
| TOTAL EQUITY & LIABILITIES | 29,919.70 | 29,020.50 |



Sharon Bio - Medicine Limited
Cash Flow Statement For Period Ended Sep 30, 2021 (Standalone)

₹ in Lakhs

| Sr. No | Particulars | Six Months ended Sep 30, 2021 | | Year ended March 31, 2021 | |
|----------|--|-------------------------------|-----------------|---------------------------|-----------------|
| A | Cash Flow From Operating Activities | | | | |
| | Net Profit / (Loss) Before Tax | | 897.11 | | 1,404.66 |
| | Adjustments for : | | | | |
| | Depreciation / amortisation | 524.92 | | 1,087.66 | |
| | Loss/(Gain) on sale of fixed assets | 0.03 | | (2.15) | |
| | Expected Credit Loss reversal | (0.06) | | (9.38) | |
| | Liability written back | - | | (90.82) | |
| | Unrealised (gain) / loss on foreign exchange | 55.86 | | (3.84) | |
| | Debtors written back | - | | (6.58) | |
| | Interest income | (37.43) | | (46.94) | |
| | Loss on sale of MEIS | - | | 2.65 | |
| | Bad Debts | - | | 11.04 | |
| | | | 543.31 | | 941.62 |
| | Operating Profit before working capital changes | | 1,440.42 | | 2,346.28 |
| | Adjustment for : | | | | |
| | (Increase)/Decrease in Inventory | 493.46 | | (932.12) | |
| | (Increase)/Decrease in Trade Receivables | 64.33 | | (657.96) | |
| | Increase/(Decrease) in Trade Payables | 64.29 | | (568.44) | |
| | Increase/(Decrease) in Other Current Liabilities | (109.96) | | 421.83 | |
| | Increase/(Decrease) in Current Financial Liabilities | (0.39) | | 9.40 | |
| | Increase/(Decrease) in Long Term Provisions | 54.81 | | 219.28 | |
| | Increase/(Decrease) in Short Term Provisions | (28.93) | | 11.95 | |
| | (Increase)/Decrease in Other Current Assets | 244.86 | | (407.49) | |
| | (Increase)/Decrease in Other Non Current Assets | (2.90) | | (13.78) | |
| | Increase/(Decrease) in Long Term Loans & Adv | (26.52) | | (37.90) | |
| | Change in Working Capital | | 753.05 | | (1,955.23) |
| | Cash Generated From Operations | | 2,193.47 | | 391.05 |
| | Net Income Tax (paid) / refunds | | 13.59 | | 25.34 |
| | Net Cash Flow From / (used in) Operating Activities (A) | | 2,207.06 | | 416.39 |
| B | Cash Flow From Investing Activities | | | | |
| | Purchase of Property, plant & Equipment (PPE) | (233.40) | | (432.44) | |
| | Proceeds from sale of PPE/Capitalisation of PPE | 0.28 | | 2.80 | |
| | Interest received | 35.75 | | 44.78 | |
| | Investments in Gratuity Trust | - | | (0.13) | |
| | | | (197.35) | | (384.99) |
| | Net Cash Flow From / (used in) Investing Activities (B) | | (197.35) | | (384.99) |
| C | Cash Flow From Financing Activities | | | | |
| | (Increase)/Decrease in Other Financial Assets | 1.68 | 1.68 | 2.16 | 2.16 |
| | Net Cash Flow From / (used in) Financing Activities (C) | | 1.68 | | 2.16 |
| | Net Inc/(Dec) in Cash and Cash Equivalents (A+B+C) | | 2,011.38 | | 33.59 |
| | Cash and Cash Equivalents at the beginning of the year | 3,188.61 | | 3,155.02 | |
| | Cash and Cash Equivalents at the end of the year | 5,199.98 | | 3,188.61 | |
| | | | 2,011.38 | | 33.59 |
| | Components of Cash & Cash Equivalents | | | | |
| | Cash on Hand | 2.87 | | 1.41 | |
| | Current Account | 1,384.72 | | 1,274.80 | |
| | Unpaid Dividend Account (Earmarked) | 12.78 | | 12.78 | |
| | Deposits & Bank Balance held as restricted use | 3,799.62 | | 1,899.62 | |
| | | 5,199.98 | | 3,188.61 | |



Notes:

1. Sharon Bio-Medicine Limited, has undergone a corporate insolvency resolution process ("CIRP") under the aegis of the Insolvency and Bankruptcy Code, 2016 ("IBC"). The CIRP commenced on April 11, 2017 and culminated with the approval of a resolution plan by the National Company Law Tribunal ("NCLT"), Mumbai, vide its order dated March 8, 2018 in respect of the Company. The successful resolution applicant is Peter Beck and Partner Vermoögensverwaltung Ltd. ("PBP") ("Resolution Applicant"). The implementation of the Resolution Plan was challenged by the erstwhile promoters before the National Company Law Appellate Tribunal ("NCLAT") which saw it fit to dismiss the appeals and vacate its previous status quo order, vide its order dated December 19, 2018. Thereafter, the erstwhile promoters filed an appeal before the Supreme Court of India on February 5, 2019, which was dismissed by Supreme Court on April 5, 2019.

Since the Resolution Plan was not implemented, SBI on behalf of the committee of creditors ("CoC") referred the matter to the NCLT. The NCLT vide order dated February 2, 2021, allowed PBP further time to implement the Resolution Plan, directed PBP to infuse funds into the Company in terms of the Resolution Plan and waived the requirement of the bank guarantee ("NCLT Order"). The CoC has filed an appeal with the NCLAT against the NCLT Order. As on date, the matter is pending for adjudication by NCLAT.

2. As per resolution plan approved by Hon'ble NCLT, Mumbai; the company has undertaken a selective capital reduction from 118,935,700 Equity shares to 57,55,625 Equity shares of Rs. 2/- each in the financial year 2020-21 for which the relevant Stock Exchanges have given their in-principle approval.
3. The resolution plan is not yet implemented as the Company is facing procedural delays to obtain necessary approvals from regulatory authorities, due to which
 - a) No impact has been given in the financials in relation to the implementation of the resolution plan except as indicated in the point 2. Above.
 - b) The company assesses certain items based on the resolution plan which are likely to reduce loss and increase Other Equity by Rs 172.40 Cr based on the contractual cash flows. The impact of resolution plan based on discounted cash flows as per IND AS 109 could not be assessed due to pending implementation of resolution plan as at the reporting date. The impact on account of proposed settlement of creditors against their claims during CIRP, could not be assessed as it needs to be addressed case to case basis.
 - c) The Foreign Currency Convertible Bonds amounting to Rs. 169.69 Crores are considered to be part of Liabilities. The same is not bifurcated into debt and equity component as stipulated in IND AS 109. The Company is of the opinion that the same will be dealt in line with the Resolution Plan.
 - d) In accordance with IND AS 109, Loans, liabilities shall be presented either as at amortized cost or as at fair value through profit or loss (FVTPL). However, term Loans amounting to Rs. 360.55 Cr are stated at cost, on account of pending implementation of the resolution plan as the amortized Cost and the effective interest rate is not ascertainable.
 - e) Pursuant to the Resolution Plan, the Resolution Applicants (RA) have infused a sum of Rs. 10.06 Crores, pending allotment within the stipulated time as per the Companies Act 2013. This amount has been disclosed under Other Current Liabilities as Share Application Money Pending Allotment.



Two handwritten signatures in blue ink. The first is a stylized signature, and the second is a more cursive signature.

4. Pending implementation of resolution plan, finance Cost & Interest has not been accrued & diluted EPS is not calculated during the quarter ended September 30, 2021.
5. The above unaudited financial results are approved by Chief Executive Officer and Vice President Finance & Accounts in the meeting held on November 3, 2021.
6. Pending implementation of Resolution plan, management finds it impracticable to determine tax base of items of assets and liabilities and hence has not measured deferred tax assets and deferred tax liabilities as required by Ind AS 12.
7. The employees' gratuity fund scheme is the Company's defined benefit plan. The present value of the obligation under the said defined benefit plan as per IND AS 19 is determined on the basis of actuarial valuation from an independent actuary using the Projected Unit Credit Method.
8. The Company is in process of identification of parent assets and its components in the property plant and equipment, as required under Ind AS 16.
9. The process of identifying Cash Generating Units as required under Ind AS 36 for mandatory impairment testing shall be completed post implementation of the Resolution Plan.
10. The financial report has been prepared on a going concern based on the approval of the Resolution Plan by the adjudicating authority. The management has drawn detailed business plan which contemplates continuity of normal business activities and the realisation in the ordinary course of business. The business plan also contemplates by undertaking number of steps that enables the Company to raise meaningful funds and allow it to continue as a going concern.
11. The reporting of financial statement is for Pharmaceuticals segment. The company has no other segment that fulfils the quantitative threshold as specified under Ind AS - 108 "Operating Segments". Accordingly, segment reporting is not required.
12. Unpaid and unclaimed dividend Rs 12.78 lakhs could not be transferred to Investors protection Fund of Central Government since there are no authorized persons registered with MCA, the e-filings could not be completed.
13. Previous years/ quarter's figures have been re-grouped and re-arranged wherever considered necessary.

Place: Mumbai

Date: 3rd November, 2021

For Sharon Bio- Medicine Limited



A handwritten signature in black ink, appearing to read "Kaushik Banerjee".

Kaushik Banerjee
Chief Executive Officer

A handwritten signature in blue ink, appearing to read "Dinesh Sharma".

Dinesh Sharma
VP- Finance



Head Office : 212, 314-316, Nirman Vyapar Kendra, Sector-17, Vashi, Navi Mumbai - 400 703
Branch Office : 102, Susheel House, Final Plot No. 61/1, Old Thana Naka Road, Panvel - 410 206.

**Independent Auditor's Limited Review Report for the quarterly and year to date
September 30, 2021 pursuant to the regulation 33 of the SEBI (Listing Obligation and
Disclosure Requirements) Regulations, 2015, as amended.**

To
Kaushik Banerjee
Chief Executive Officer
Sharon Bio-Medicine Limited

1. We have reviewed the accompanying statement of Unaudited Financial Results of Sharon Bio-Medicine Limited for the Quarter and year to date April 01, 2021 to September 30, 2021.
2. This statement is the responsibility of the Company's Management and has been approved by the Chief Executive Officer has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.




5. The company was under Corporate Insolvency Resolution Process (hereinafter referred as 'CIRP' or 'CIR Process') under Insolvency and Bankruptcy Code, 2016 (hereinafter referred as 'IBC' or 'the Code') with Mumbai Bench of National Company Law Tribunal (hereinafter referred as 'NCLT'). Consequently, the NCLT vide notification MA 12/2018 in CP No. 246/I&BP/NCLT/MAH/2017 under section 30(6) of IBC, 2016 has proposed certain settlements or restructuring plans of all claims based on the terms as mentioned in the resolution plan.
6. As per information and explanations given by the management, the impact of the approved settlement/restructuring plan on the financial statements has not been considered in the previous financial years 2017-18, 2018-19, 2019-20, 2020-21 as well as current quarter ending September 30, 2021. Attention is drawn to Note No 3 of Financial Results September 30, 2021.
7. As per Section 134 of the Companies Act, 2013, the Financial Results of a company are required to be authenticated by the chairperson of the board of directors, where authorized by the board or at least two directors, of which one shall be the managing director or the CEO (being a director), the CFO and the Company Secretary where they are appointed.

As the board is yet to be reconstituted post approval of restructuring plan by NCLT, the financial statements are being approved by Mr. Kaushik Banerjee, CEO of the Company appointed by the monitoring agency and the Company Secretary.

Emphasis of Matter

1. Attention is drawn on Note no 2 of Financial Results for selective Reduction in Equity Share Capital made by the Company as per Resolution Plan approved by Hon'ble NCLT, Mumbai; accordingly, the paid-up equity shares have been reduced to 57,55,625 Equity Shares of Rs. 2/- each during the Financial year 2020-21. As a result, the accumulated losses have been reduced by Rs 2,263.60 lakhs.
2. The Company as on September 30, 2021 has accumulated losses of Rs.73,819.89 Lakhs (Previous Quarter ended on June 30, 2021 Rs. 74,267.58 Lakhs) (Excluding Share Premium and Revaluation Reserves) and its current liabilities exceeded its total Assets by Rs 5176.80 Lakhs. The financial results are drawn on going concern basis, considering the NCLT order referred in initial paragraph of the Limited Review Report statement.
3. Attention is drawn to Note No 3 & 4 of the Financial Results for non-implementation of resolution plan with respect to reinstatement of asset and liabilities & non-provision of Finance Cost and Interest on Statutory Dues which has not been accrued for the Financial Year 2017-18, 2018-19, 2019-20 & 2020-21 and Quarter ended September 30, 2021.
Due to pending implementation of resolution plan, it is impracticable to determine the effect of resolution plan on the financial statement.




4. Departure with Indian Accounting Standards:

- a. Attention is drawn to Note No.3 c in the Financial Results; the Foreign Currency Convertible Bonds amounting to Rs.169.69 Crores are classified as Liabilities in the Financials. In accordance with IND AS 109, such bonds should be split into debt and equity components. The classifications in the financials are a departure with the applicable Financial Reporting Framework.
 - b. Attention is drawn to Note No. 3 d in the Financial Results, Term Loans amounting to Rs. 360.55 Lakhs are not considered at amortized cost in accordance with IND AS 109
 - c. Attention is drawn to Note No.8 in the Financial Results, the Company has not identified components in the Fixed Assets for want of component and its parent asset based information. This is not in line with the norms stipulated under IND AS 16 Property, Plant & Equipment.
 - d. Attention is drawn to Note No.9 in the Financial Results the Company has not conducted the mandatory impairment testing as required under IND AS 36 Impairment of Assets.
 - e. Attention is drawn to Note No.6 in the Financial Results the Company for non-recognition of deferred tax assets & liabilities as per IND AS 12.
 - f. Attention is drawn to Note No. 4 in Financial Results the Company for not determining Diluted EPS.
5. Attention is drawn to Note No 14 regarding transfer of Unpaid and unclaimed dividend Rs 12.78 lakhs could not be transferred to Investors protection Fund of Central Government since there are no authorized persons registered with MCA, the e-filings could not be completed.
6. Attention is drawn on Note no 13 of Financial Results for existing installed capacity of the Company, the current management is in the process of reviewing and reassessing the installed capacity of its manufacturing sites. The licensed & installed capacities are as certified by the earlier management.



7. The Auditors qualifications, observations and matters emphasised in the printed Annual Report of FY 2020-21 and those pertaining to June 2021 results, may continue to be relevant for half year ended Sept 2021.

For M/s. E.A. Patil & Associates LLP
Chartered Accountants
Firm Registration No. 117371W / W100092



CA. Ujwal N Landge
Partner

Membership No. 108231

Place: Vashi, Navi Mumbai.

Date: 3rd November, 2021

UDIN as per ICAI - 21108231AAAAMH6522

